Gilead to buy biotech firm Ouro Medicines in over $2 billion deal

March 23 (Reuters) – Gilead Sciences said on Monday it would buy privately held biotech firm Ouro Medicines in a deal worth up to $2.18 billion.

(Reporting by Mariam Sunny in Bengaluru; Editing by Shilpi Majumdar)

Brought to you by www.srnnews.com